Alethiomics is an Oxford University spin-out applying innovations in single-cell multi-omic analysis to the development of novel therapeutics for myeloproliferative neoplasms (MPNs).
MPNs are a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. While currently available treatments can relieve symptoms, they do not tackle the underlying disease drivers meaning patients have poor prognosis.
The company’s founders have pioneered the use of single-cell multi-omics approaches to better understand the biology of MPNs and to discover novel molecular targets as the basis for drug discovery. They have also developed bespoke platforms for target validation to accelerate successful translation to the clinic.
The Alethiomics TARGET-seq platform simultaneously detects DNA mutations, the RNA transcriptome and cell surface proteins from individual cells to provide a holistic understanding of pathologies and more intelligent target identification. Based on these discoveries, the company is now developing therapeutics that it will advance through discovery to clinical development.
Founded in 2021, the company has received £6m in seed financing from Oxford Science Enterprises.
Subscribe for alerts on new companies featured on Startups.Bio
Therorna was founded in China in 2021, leveraging its proprietary circular RNA technology platform to develop next-generation vaccines and innovative therapies. Compared with linear RNA, …
Tamarix Pharma was founded in 2021 based on technology licensed from the National Institute for Biotechnology in the Negev (Israel) and is focused on developing …
BacVax is a spin-off from the University of Arizona with a novel approach to developing vaccines against bacterial infections by mapping the proteins on the …
Lento Bio was founded in 2022 in collaboration with Ichor Life Sciences and Clarkson University’s Shipley Center for Innovation, with the goal to develop effective, …
Oravax Medical is developing proprietary technologies for the oral delivery of vaccines. The company was founded in 2021 as a joint venture between Oramed Pharmaceuticals, …
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Tags:
Get 15% off a VentureRadar Subscription
Pay through the following Startups.Bio discount page when you upgrade. Use it now or save it for later.
